Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Accentuates The Positives Of Heart Failure Drug Entresto At ACC

Executive Summary

Clinicians hail the efficacy data behind the new therapy, but some say reimbursement requirements are too onerous, resulting in slow uptake.

You may also be interested in...



Novartis' Late Bloomer Entresto Leads Take-Off Of Heart Failure Market

Market snapshot: Growth of Novartis' Entresto along with greater use of SGLT-2 inhibitors and the entry of new branded drugs will boost sales of drugs for chronic heart failure from $4.6bn in 2017 to $10.1bn in 2026, despite wide availability of generics, according to a new Datamonitor forecast.

Novartis Woos Payers With Data Showing Entresto Earns Its Keep

With Entresto sales slowly climbing to $53m in third quarter, Novartis releases data supporting value of heart failure drug in preventing costly hospitalizations at the annual American Heart Association meeting.

Tekturna’s Loss May Be Entresto’s Gain As Novartis Hopes For Change In The ATMOSPHERE

Strength of Novartis’ new heart failure drug Entresto contrasts with yet another failed outcomes study for its old renin inhibitor Tekturna.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS057566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel